

Dear Healthcare Professional,

Supply of Accuretic[™] 10mg/12.5mg tablets in alternative (Canadian) artwork to New Zealand

Pfizer has experienced a delay to the start-up of a new high-speed packing line at our German manufacturing site that that produces Accuretic[™] 10mg/12.5mg tablets (10mg quinapril / 12.5mg hydrochlorothiazide). This delay means that we have been unable to produce sufficient New Zealand labelled stock to meet demand. To ensure that patients will not be adversely affected by this lack of supply, Pfizer will be supplying Accuretic 10mg/12.5mg tablets in Canadian artwork.

Please note that the Canadian tablet formulation is identical to the New Zealand tablet formulation. Differences exist to the artwork on the carton and blister foil only. For Accuretic 10mg/12.5mg tablets, Canadian artwork, the blisters are presented as a calendar pack indicating one tablet is taken once a day. The registered dosage in New Zealand is between a half tablet to two tablets a day. Below is a side by side comparison of the current NZ and over-labelled Canadian cartons and blister foils:





The details on the Canadian artwork are:

Batch Number: CR0344 Expiry Date: 30 April 2021

This action is taking place with the knowledge of both Medsafe and PHARMAC.

Please direct all supply or medical enquiries regarding Accuretic 10mg/12.5mg tablets to Pfizer New Zealand on 0800 736 363.

Please report any suspected adverse events to the Centre for Adverse Reactions Monitoring (CARM) in Dunedin online at https://nzphvc.otago.ac.nz/reporting or by email to nzphvc@otago.ac.nz. Alternatively, suspected adverse events may be reported via email to Pfizer Drug Safety at AUS.AEReporting@pfizer.com.

Before prescribing Accuretic 10mg/12.5mg tablets please review the full data sheet available at www.medsafe.govt.nz.

Yours faithfully,

P. Geweinle

Pasquale Gargiulo

Associate Medical Director

Pfizer New Zealand